DO-1 is a highly selective small molecule inhibitor of the MET kinase. 

DO-1 was initially  tested in a healthy volunteer study where initial data on pharmacokinetics, food effect and safety were obtained .  A  further phase 1/1b patient study led to teh identification of a recommended Phase 2 Dose (250mg BID)  and promising signs of clinical activity were observed in MET exon 14 skipping patients as well tumour shrinkage in combination with an EGFR inhibitor in EGFR TKI resistant patient.  

 DeuterOncology have a sub-license for rest of the  world outside greater China. 

DO-1 Hs746T.png
Tumour shrinkage clinic.png